Berta Saez

Berta Saez

Auto-generated profile, based on publicly available information

Berta Saez

INDIVO Group. Aragon Government Research Group B30_23R, Zaragoza, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2008 in Nature
Verified
Journal Article
Closed access
PDF file
TTThorgeir E. Thorgeirsson
Thorgeir E. Thorgeirsson
FGFrank Geller
Frank Geller
PSPatrick Sulem
Patrick Sulem
TRThorunn Rafnar
Thorunn Rafnar
AWAnna Wiste
Anna Wiste
KSKari Stefansson
Kari Stefansson

12 August 2011 in Cancers
Verified
Journal Article
Open access
PDF file
Manuel ArrueboManuel Arruebo
Manuel Arruebo
Nuria VilaboaNuria Vilaboa
Nuria Vilaboa
BSBerta Sáez-Gutierrez
Berta Sáez-Gutierrez
JLJulio Lambea
Julio Lambea
ATAlejandro Tres
Alejandro Tres
ÁGÁfrica González-Fernández
África González-Fernández
Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.

1 July 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JGJulius Gudmundsson
Julius Gudmundsson
PSPatrick Sulem
Patrick Sulem
VSValgerdur Steinthorsdottir
Valgerdur Steinthorsdottir
JBJon T Bergthorsson
Jon T Bergthorsson
GTGudmar Thorleifsson
Gudmar Thorleifsson
KSKari Stefansson
Kari Stefansson

25 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe ENGAGE Consortium
The ENGAGE Consortium
TTThorgeir E Thorgeirsson
Thorgeir E Thorgeirsson
DGDaniel F Gudbjartsson
Daniel F Gudbjartsson
ISIda Surakka
Ida Surakka
JVJacqueline M Vink
Jacqueline M Vink
KSKari Stefansson
Kari Stefansson

18 January 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TRThorunn Rafnar
Thorunn Rafnar
PSPatrick Sulem
Patrick Sulem
SSSimon N Stacey
Simon N Stacey
FGFrank Geller
Frank Geller
JGJulius Gudmundsson
Julius Gudmundsson
KSKari Stefansson
Kari Stefansson

27 April 2008 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSSimon N Stacey
Simon N Stacey
AMAndrei Manolescu
Andrei Manolescu
PSPatrick Sulem
Patrick Sulem
STSteinunn Thorlacius
Steinunn Thorlacius
SGSigurjon A Gudjonsson
Sigurjon A Gudjonsson
KSKari Stefansson
Kari Stefansson